P

Profound Medical

MRI-guided, incision-free prostate ablation platform

Field Service Engineer

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Bachelor of Science (BS)
Newark, NJ, USA
RemotePrimarily U.S. onsite customer visits; travel required 80% of the time. Preferred location is the Northeast, near an airport.
Field ServiceEquipment Field Service

About the job

Requirements
  • A B.S. in Biomedical Engineering, Biotech, Electrical Engineering, or Electronics-related fields, or equivalent experience.
  • Ability to travel on short notice in the United States 80% of the time.
  • Ability to respond to inquiries and communicate and interact reliably with health care professionals and scientists who possess advanced degrees.
  • Strong multitasking, self-sufficiency, and resourcefulness.
  • Critical thinking, analytical troubleshooting, and problem-solving skills.
  • Ability to work independently and as part of a team, with initiative and accountability.
  • Verbal, written, Microsoft Office, computer, technical data, networking, and presentation skills, including the ability to explain complex technical issues clearly.
  • Organizational skills and ability to follow through and meet deadlines.
  • Working knowledge of quality management systems such as ISO 9001 or ISO 13485.
  • Willingness and flexibility to work different shifts to accommodate customer needs.
Responsibilities
  • Perform and support product installation activities, including site assessments, installations, maintenance, and troubleshooting.
  • Conduct MR testing to support product development, typically at hospital sites during off-hours, with schedule and travel flexibility.
  • Act as the primary link between customers and the company as needed.
  • Document service records and activities according to company quality management system processes for service visits and field upgrades.
  • Calibrate company products as required.
  • Execute test and troubleshooting protocols for hardware, software, and systems aspects of company products.
  • Investigate methods to increase efficiency in MR testing and development activities.
  • Regularly participate in MRI phantom testing for new product revisions.
  • Support the execution and improvement of the field service strategy for company products.
  • Organize and prioritize the schedule according to customer requirements, determining needs for immediate attention, onsite visits, and remote assistance.
  • Enter parts orders and generate and follow up on parts quotes when required.
  • Work with information technology departments at customer sites to establish proper equipment networking.
  • Contribute to establishing a professional service team.
  • Create documentation and electronic reference materials to support product field service, including installation and troubleshooting manuals.
  • Participate in product design activities, representing serviceability and product quality for internal customers and end users.
  • Work with engineering, quality, and operations teams to resolve technical issues.
  • Execute other ad-hoc projects as assigned by the manager.
Desired Qualifications
  • Previous field service experience.
  • Experience with MRI operations.
  • Working knowledge of operating multiple original equipment manufacturer MRI systems.
  • Preferred location is in the Northeast, with close proximity to an airport.

About the company

Profound Medical focuses on incision-free therapies for diseased tissue with its TULSA-PRO system for prostate ablation. The device uses real-time MRI guidance, robotic transurethral ultrasound, and closed-loop temperature control to ablate targeted prostate tissue in a single outpatient session. Revenue comes from a razor-blade model: upfront capital equipment plus recurring income from consumables, leases, and services, with AI-powered TULSA-AI modules under development. The goal is to expand precise, noninvasive prostate treatment to major hospitals and imaging centers while growing recurring revenue and usability.

Company Size

51-200

Company Stage

Post IPO Equity

Headquarters

Mississauga, Canada

Founded

2008

Get referred to Profound Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit CAD 2.5 million; excluding timing, it reached CAD 5.6 million.
  • CMS 2027 proposed OPPS payment rises 14.9% to $15,494 per procedure.
  • Covered lives expanded by 18.3 million in Q2, reaching nearly 30 million.

What critics are saying

  • Q2 still showed a CAD 9.5 million loss and only 84 installed systems.
  • The ASC reimbursement cut to $6,866 exposes a weak hospital-cost filing.
  • CAPTAIN disappointment would freeze payer adoption and keep Profound dependent on dilutive capital.

What makes Profound Medical unique

  • TULSA-PRO remains the only AI-guided, MRI-guided robotic prostate ablation platform.
  • Sunnybrook-originated IP and regained Canadian rights strengthen clinical credibility and control.
  • Exclusive Getz distribution in Australia and New Zealand expands reach without building everything.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

9%
Yahoo Finance
Aug 7th, 2026
Profound Medical Q2 revenue rises 12% to $1.8M, shipment delays mask 153% growth

Profound Medical reported Q2 revenue of CAD 2.5 million, up 12% year over year, though CAD 3.1 million in TULSA shipments shifted from June to July. Excluding this timing issue, revenue would have reached CAD 5.6 million, representing 153% growth. The company maintained its 2026 revenue target of CAD 25 million and gross-margin guidance of at least 70%. Gross margin improved to 78% from 73% in the prior-year period. Profound's TULSA-PRO qualified sales pipeline reached CAD 70 million, with 84 systems installed. Same-store utilisation declined sequentially due to temporary site issues but remained up year over year. The company reported a net loss of CAD 9.5 million, or CAD 0.26 per share, compared with a loss of CAD 15.7 million in Q2 2025. Cash stood at CAD 38.3 million as of 30 June.

Yahoo Finance
May 3rd, 2026
Profound Medical expected to breakeven by 2028 with 53% annual growth target

Profound Medical Corp., a commercial-stage medical device company developing AI-powered, MRI-guided therapeutic systems, is expected to reach profitability by 2028, according to five industry analysts. The company, with a CA$341 million market capitalisation, posted a US$43 million loss for its most recent financial year ending 31 December 2025. Analysts forecast Profound Medical will post its final loss in 2027 before turning a profit of US$9.4 million in 2028, approximately two years from now. Achieving this requires an average annual growth rate of 53%. The company has managed capital prudently, with debt comprising just 6.8% of equity, predominantly funding operations through equity capital. This low debt obligation reduces investment risk for the loss-making company.

Yahoo Finance
Apr 25th, 2026
Profound Medical presents TULSA prostate data showing faster recovery vs. robotic surgery, targets 600K patients with $500K capital model

Profound Medical showcased clinical data and software upgrades for its TULSA prostate treatment system at a recent conference. CAPTAIN-era data showed TULSA patients returned to work faster than robotic prostatectomy patients (10 versus 19 days) with zero hospitalisations versus over 6%. The company is scaling AI tools including Thermal Boost Contouring Assistant and partnering with Siemens and Cook on compact interventional MRI systems. Revenue grew from approximately CAD 10 million in 2024 to CAD 16 million in 2025, with management projecting high double-digit growth and potential profitability at around 200 sites. TULSA uses MRI-guided ultrasound ablation without incisions, positioning itself between robotic prostatectomy and focal therapy. The company estimates a 600,000-patient addressable market with roughly $500,000 capital costs plus $5,500 per-patient disposables.

Yahoo Finance
Mar 6th, 2026
Profound Medical reports $6M Q4 revenue, completes CAPTAIN trial with data due March 13

Profound Medical reported Q4 2025 revenue of $6.0 million, a 43% year-on-year increase, comprising $2.3 million in recurring revenue and $3.7 million from capital equipment sales. Gross margin declined to 67% from 71% the previous year, whilst the company posted a net loss of CAD 8.2 million with CAD 59.7 million cash on hand. The company announced completion of recruitment and treatments for its CAPTAIN trial, comparing its technology to robotic radical prostatectomy for localised prostate cancer. Primary safety and quality-of-life endpoints will be presented at the European Association of Urology meeting on 13 March. Profound ended 2025 with 78 TULSA-PRO sites and a 110-system pipeline, targeting profitability around $80-85 million revenue.

Kilmer Lucas
Feb 12th, 2026
INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing tulsa procedure for prostate disease. February 12, 2026 Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI. In a statement, Raphael Ronen, co-executive director of INOVAIT, commented, "The Mount Logan Award recognizes an INOVAIT industry member who has consistently exceeded project milestone expectations, reached new heights as a Canadian company, and stood out internationally. Profound Medical has achieved significant milestones and international acclaim over the last year, including treating their 4,000th TULSA Procedure patient, securing new U.S. reimbursement codes from Medicare, and establishing strategic partnerships to expand patient access globally, and is, therefore, worthy of celebrating with the Mount Logan Award." The iMRI TULSA Procedure, performed using the TULSA-PRO system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (BPH, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to 'kill temperature' (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. Arun Menawat, CEO and chairman of Profound, remarked, "We are incredibly honored to receive this award as we work to drive widespread global commercialization of a home-grown Canadian medical innovation. While currently only one TULSA-PRO system install resides in Canada, we hope to change that moving forward as we just recently regained exclusive distribution rights in the country from a previous partner. In the meantime, the importance of that single current commercial placement in Canada can't be overstated. Toronto's renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures despite it not being covered by a provincial health insurance plan. Moving forward, as user interest in Profound's technologies continues to build, we are deploying our own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world." Mathieu Burtnyk, president of Profound, added, "We are deeply grateful to INOVAIT for supporting a vision where AI enabled, image guided therapies like TULSA-PRO are not only developed in Canada, but lead the world. That support gives companies like ours the momentum to turn bold ideas into real clinical impact."